What SEC filings does Werewolf Therapeutics, Inc. submit to the SEC?

Werewolf Therapeutics, Inc. (HOWL) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about HOWL?

A Form 4 for HOWL discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from Werewolf Therapeutics, Inc.?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for HOWL?

The 10-K is Werewolf Therapeutics, Inc.'s annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all HOWL SEC filings directly on EDGAR?

You can view all historical Werewolf Therapeutics, Inc. filings on the SEC EDGAR company page for HOWL. Each filing card on this page links directly to the original SEC document.

How often does Werewolf Therapeutics, Inc. file with the SEC?

Werewolf Therapeutics, Inc. files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling HOWL shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

HOWL SEC Filing News — Werewolf Therapeutics, Inc.

Latest SEC filings for Werewolf Therapeutics, Inc. (HOWL) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-08-21.

Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. Its lead product candidates are WTX-124, a conditionally activa…

Sector: Healthcare Industry: Biotechnology Market Cap: $50.5M CIK: 1785530

Total Filings

Bullish Classifications

Bearish Classifications

Insider Transactions

Material Events (8-K)

Periodic Reports

Rule-based classifications for HOWL currently lean bearish. Of the 20 filing records displayed, 4 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 0 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.

HOWL Filing Activity Snapshot 2026-06-16 — 2026-08-21

Insider Transactions (Form 4)

0 buys vs 4 sells

Net insider selling in this period — insiders sell for many reasons beyond conviction.

Largest Form 144 Filing

$173.8K

RA CAPITAL MANAGEMENT, L.P. (10% Owner) · 2026-06-16

448,836 shares · Form 4

Form 144 Notices

Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.

Insider Transactions 4 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 4 filings in this group are Form 4s for Werewolf Therapeutics, Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 4 insider filings shown, the breakdown is 4 open-market sale. 4 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Open-market sale ×4: The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Form 4 Open-market sale Insider Selling 2026-07-08

HOWL insider EVNIN LUKE (Director) sold 143,199 shares (~$44.7K)

EVNIN LUKE, listed as Director at Werewolf Therapeutics, Inc., reported an open-market sale of 143,199 HOWL shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	35,770	$0.32	$11.4K
`S`	Open-market sale	107,429	$0.31	$33.3K

Filing: Form 4 (Insider Transaction) Insider: EVNIN LUKE (Director) Shares: 143,199 Est. Value: $44.7K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-06-29

HOWL insider EVNIN LUKE (Director) sold 157,084 shares (~$47.1K)

EVNIN LUKE, listed as Director at Werewolf Therapeutics, Inc., reported an open-market sale of 157,084 HOWL shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	157,084	$0.30	$47.1K

Filing: Form 4 (Insider Transaction) Insider: EVNIN LUKE (Director) Shares: 157,084 Est. Value: $47.1K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-06-22

HOWL insider RA CAPITAL MANAGEMENT, L.P. (10% Owner) sold 416,911 shares (~$145.9K)

RA CAPITAL MANAGEMENT, L.P., listed as 10% Owner at Werewolf Therapeutics, Inc., reported an open-market sale of 416,911 HOWL shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	389,216	$0.35	$136.2K
`S`	Open-market sale	27,695	$0.35	$9.7K

Filing: Form 4 (Insider Transaction) Insider: RA CAPITAL MANAGEMENT, L.P. (10% Owner) Shares: 416,911 Est. Value: $145.9K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-06-16

HOWL insider RA CAPITAL MANAGEMENT, L.P. (10% Owner) sold 448,836 shares (~$173.8K)

RA CAPITAL MANAGEMENT, L.P., listed as 10% Owner at Werewolf Therapeutics, Inc., reported an open-market sale of 448,836 HOWL shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	159,119	$0.40	$63.6K
`S`	Open-market sale	11,322	$0.40	$4.5K
`S`	Open-market sale	120,216	$0.39	$46.9K
`S`	Open-market sale	8,554	$0.39	$3.3K
`S`	Open-market sale	139,686	$0.37	$51.7K
`S`	Open-market sale	9,939	$0.37	$3.7K

Filing: Form 4 (Insider Transaction) Insider: RA CAPITAL MANAGEMENT, L.P. (10% Owner) Shares: 448,836 Est. Value: $173.8K

View on SEC EDGAR → Open Filing Document →

Proposed Insider Sales 12 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. Werewolf Therapeutics, Inc. has 12 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.